Dash Sabyasachi, Dash Chandravanu, Pandhare Jui
Weill Cornell Medicine, Department of Pathology and Laboratory Medicine, Cornell University, New York, NY 10065, USA.
Center for AIDS Health Disparities Research, Meharry Medical College, Nashville, TN 37208, USA.
Noncoding RNA. 2021 Sep 22;7(4):60. doi: 10.3390/ncrna7040060.
The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 (2019-nCoV) has devastated global healthcare and economies. Despite the stabilization of infectivity rates in some developed nations, several countries are still under the grip of the pathogenic viral mutants that are causing a significant increase in infections and hospitalization. Given this urgency, targeting of key host factors regulating SARS-CoV-2 life cycle is postulated as a novel strategy to counter the virus and its associated pathological outcomes. In this regard, Poly (ADP)-ribose polymerase-1 (PARP-1) is being increasingly recognized as a possible target. PARP-1 is well studied in human diseases such as cancer, central nervous system (CNS) disorders and pathology of RNA viruses. Emerging evidence indicates that regulation of PARP-1 by non-coding RNAs such as microRNAs is integral to cell survival, redox balance, DNA damage response, energy homeostasis, and several other cellular processes. In this short perspective, we summarize the recent findings on the microRNA/PARP-1 axis and its therapeutic potential for COVID-19 pathologies.
由新型冠状病毒SARS-CoV-2（2019-nCoV）引起的COVID-19大流行已给全球医疗保健和经济带来巨大破坏。尽管一些发达国家的感染率已趋于稳定，但仍有几个国家受到致病性病毒突变体的影响，这些突变体导致感染和住院人数大幅增加。鉴于这种紧迫性，将调节SARS-CoV-2生命周期的关键宿主因子作为对抗该病毒及其相关病理结果的新策略。在这方面，聚（ADP）-核糖聚合酶-1（PARP-1）越来越被认为是一个可能的靶点。PARP-1在癌症、中枢神经系统（CNS）疾病和RNA病毒病理学等人类疾病中已得到充分研究。新出现的证据表明，微小RNA等非编码RNA对PARP-1的调节对于细胞存活、氧化还原平衡、DNA损伤反应、能量稳态和其他几个细胞过程至关重要。在这篇简短的综述中，我们总结了关于微小RNA/PARP-1轴的最新发现及其对COVID-19病理学的治疗潜力。
